Comparison of the Roche Cobas® 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia

Samuel Phillips, Suzanne M. Garland, Jeffery H. Tan, Michael A. Quinn, Sepehr N. Tabrizi

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)


Background: The recently FDA (U.S. food and drug administration) approved Roche Cobas® 4800 (Cobas) human papillomavirus (HPV) has limited performance data compared to current HPV detection methods for test of cure in women undergoing treatment for high grade lesions. Objective: Evaluation of Cobas HPV assay using historical samples from women undergoing treatment for cervical dysplasia. Study design: A selection of 407 samples was tested on the Cobas assay and compared to previous results from Hybrid Capture 2, HPV Amplicor and Roche Linear Array. Results: Overall, a correlation between high-risk HPV positivity and high grade histological diagnosis was 90.6% by the Cobas, 86.1% by Hybrid Capture 2, 92.9% by HPV Amplicor and 91.8% by Roche Linear Array. Conclusion: The Cobas HPV assay is comparative to both the HPV Amplicor and Roche Linear Array assays and better than Hybrid capture 2 assay in the detection of High-Risk HPV in women undergoing treatment for cervical dysplasia.

Original languageEnglish
Pages (from-to)63-65
Number of pages3
JournalJournal of Clinical Virology
Publication statusPublished - Jan 2015
Externally publishedYes


  • Amplicor
  • Diagnostic
  • Human papillomavirus
  • Hybrid capture
  • Linear array
  • Roche cobas

Cite this